On April 25, 2023, the FDA accelerated approval of the antisense oligonucleotide therapy tofersen (Qalsody) for the treatment of amyotrophic lateral sclerosis (ALS) in patients with superoxide dismutase 1 (SOD1) mutations. This is the first gene-targeted therapy for ALS.

ALS, commonly known as ALS, is a progressive neurodegenerative disease characterized by progressive skeletal muscle atrophy, weakness, and fascicular fibrillation. The average survival time of patients is 3 to 5 years. The most common cause of death is respiratory failure. SOD1-ALS is a rare genetic form of ALS, accounting for only 2% of the approximately 168,000 ALS cases worldwide, most patients with rapid disease progression, survival after onset of less than three years.

Pre: The annual bleeding rate of patients was reduced by 71%, and Pfizer's marketing application for hemophilia gene therapy was accepted by the FDA

Next: Researchers at Zhejiang University School of Medicine have revealed that the concept of targeting DDK can improve the efficacy of immunotherapy for liver cancer